Silence Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The phase II SANRECO trial of divesiran in polycythemia vera showed 88% response versus 18% for placebo, with robust efficacy at both Q6- and Q12-week dosing and a favorable safety profile. Plans are underway for a phase III trial with quarterly dosing and further regulatory engagement.
-
The session highlighted progress on a siRNA-based pipeline, with the lead PV program nearing phase II data readout in August. The company targets durable, less frequent dosing and a strong safety profile, with phase III and commercialization preparations underway.
-
The company highlighted its mRNAi GOLD platform and a robust pipeline led by divesiran for polycythemia vera and zerlasiran for Lp(a) lowering, both nearing pivotal milestones. Strong clinical execution, differentiated siRNA technology, and upcoming data readouts position the pipeline for significant progress in the next year.
Fiscal Year 2025
-
A proprietary siRNA platform supports three clinical programs, including phase II SLN124 for polycythemia vera and phase III-ready SLN360 for Lp(a), both showing robust efficacy and differentiated dosing. Key milestones include phase II data in Q3 2025 and strong financial runway into 2028.
-
The conference highlighted robust progress in siRNA-based therapies, with strong phase 1 and 2 data for PV and Lp(a) programs, strategic partnerships, and a solid cash runway. AI integration and regulatory flexibility are shaping R&D, while focus remains on PV trial completion and Lp(a) partnering.
-
The conference highlighted a robust siRNA pipeline with phase III-ready and first-in-class assets targeting major unmet needs in cardiovascular and hematological diseases. Strong clinical data, global regulatory support, and a solid financial runway position the company for growth.
Fiscal Year 2024
-
Strong revenue growth in 2024 was driven by collaboration milestones, while R&D investment increased for key siRNA programs. Zerlasiran's Phase III will only begin after partnering, extending cash runway into 2027, and divasteron advances in PV with promising clinical results.
-
The company highlighted strong clinical progress for its siRNA programs targeting Lp(a) and PV, with zerlasiran showing over 90% Lp(a) knockdown and divesiran nearly eliminating phlebotomy needs in PV patients. Phase 3 and 2 trials are planned, supported by a robust cash position and strategic partnerships, including AstraZeneca.
-
Key siRNA programs demonstrated strong efficacy and durability in Lp(a) and PV, with phase 3 Lp(a) trials set for mid-next year. Physician demand is high for new therapies, and partnerships with AstraZeneca and Hansoh support a robust pipeline.
-
A proprietary siRNA platform is advancing multiple clinical programs, including zerlasiran for Lp(a) and divesiran for polycythemia vera, both showing robust efficacy in early trials. With strong partnerships, a solid cash runway, and a broad pipeline, the company is poised for significant growth.
-
Precision siRNA medicines are advancing through late-stage clinical trials, targeting major unmet needs in cardiovascular and hematological diseases. Lead programs show strong efficacy and safety, with significant market potential and robust partnerships driving growth.
-
The conference highlighted strong clinical progress for siRNA programs in cardiovascular and rare blood diseases, with lead assets showing robust efficacy, safety, and infrequent dosing. Upcoming data and regulatory milestones are expected to drive further development and market differentiation.
-
The platform's siRNA technology targets major unmet needs in cardiovascular and orphan diseases, with lead programs showing robust efficacy and durability. Zerlasiran is advancing to Phase 3 for Lp(a) reduction, while the PV program aims for Phase 2 by year-end, both supported by strong partnerships and a solid cash position.
-
Divesiran in Phase 1 for PV showed strong efficacy, eliminating phlebotomy need in all well-controlled patients and reducing overall phlebotomy rates, with robust hematocrit control and favorable safety. Phase 2 is planned by year-end, with further data to come.